相关临床试验
2
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
尚未招募
1
50.0%
招募中
1
50.0%
暂无批准数据
- Max Reinhardt, former DePuy Synthes Spine worldwide president and Orthofix global spine president, has been appointed President, Healthcare at eXeX to lead commercial execution of the Canopus Surgery Intelligence platform. - Canopus is deployed across multiple hospital groups in the U.S. and U.K., having supported several thousand live surgeries, with accelerated quarter-over-quarter growth reported. - eXeX also launched Canopus Command, a portal providing hospital leadership with real-time operational visibility into every surgical case, including a novel metric called the Surgical Inquiry. - Reinhardt brings over three decades of MedTech leadership experience, including 17 years at Johnson & Johnson, to drive adoption of the touch-free, non-clinical OR workflow platform.
- DePuy Synthes has entered an exclusive distribution agreement with CGBIO for NOVOSIS, an advanced bone graft substitute containing growth factors, across the United States, Canada, and Australia. - NOVOSIS is designed to address unmet needs in orthopaedic care and is currently undergoing an FDA-approved investigational device exemption study for spine procedures. - The partnership expands DePuy Synthes' orthopaedic portfolio across spine, craniomaxillofacial, and trauma specialties with a differentiated regenerative medicine technology. - Johnson & Johnson previously secured distribution rights for NOVOSIS in Asian markets including Korea, Taiwan, Thailand, India, Hong Kong, and Macau in February 2025.
- Johnson & Johnson's Ottava Robotic Surgical System successfully met all primary safety and performance endpoints in the FORTE trial, a prospective study of 30 patients undergoing Roux-en-Y gastric bypass surgery. - Patients lost an average of 30 pounds (13.6kg) within 30 days post-surgery, with no conversions to open surgery reported during the procedures. - The company has submitted a De Novo application to the FDA based on these results and preclinical data, seeking approval for multiple gastrointestinal procedures including gastric bypass, sleeve surgeries, and upper abdominal operations. - The Ottava system features four robotic arms integrated into a standard surgical table, designed to fit existing hospital infrastructure and remove practical barriers to robotic surgery adoption.
- Johnson & Johnson is preparing a potential sale of its orthopedics unit DePuy Synthes, which could be valued at more than $20 billion according to sources familiar with the matter. - The company acquired DePuy Synthes for $21.3 billion in 2011 and announced plans in October 2025 to separate the orthopedics business within 18 to 24 months. - Several large private equity firms are considering joint bids for the unit, which generates $9.3 billion in annual sales from hip and knee replacement devices. - Bloomberg Intelligence estimates the unit could be worth about $20 billion, or $28 billion including debt, as J&J prepares financial materials for upcoming buyer meetings.
- CraniUS Therapeutics raised $20 million in Series B financing to accelerate development of NeuroPASS™, a fully implantable skull-embedded platform designed to bypass the blood-brain barrier for targeted drug delivery. - The neurotechnology company was founded by Dr. Chad Gordon, a Johns Hopkins neuroplastic surgeon, to address the clinical challenge that life-saving therapies often cannot reach the brain due to the blood-brain barrier. - The funding will support operations into 2027 and enable regulatory submissions, manufacturing scale-up, and product testing towards future commercialization of the multi-product platform. - CraniUS appointed Johnson & Johnson veteran Oray Boston Jr. to its board of directors, bringing over 35 years of global healthcare leadership experience to guide commercialization strategies.
- Johnson & Johnson CEO Joaquin Duato confirmed during the company's third-quarter earnings call that no drug pricing agreement has been finalized with the White House, despite ongoing discussions since the administration began. - The healthcare giant has not secured a Most Favored Nation drug pricing deal like competitors Pfizer and AstraZeneca, who received reprieve from threatened pharmaceutical tariffs through their agreements. - J&J reported strong third-quarter pharmaceutical performance with $15.6 billion in revenue, led by multiple myeloma drug Darzalex generating $3.7 billion worldwide sales with nearly 22% growth. - The company announced plans to spin out its orthopedics unit DePuy Synthes as a standalone company by 2027, following an 18-24 month process to separate the $9.2 billion revenue division.
- Johnson & Johnson announced plans to spin off its orthopedics business into a standalone company called DePuy Synthes within 18-24 months, generating $9.2 billion in fiscal year 2024 sales. - The separation aims to refocus J&J's medtech portfolio on higher-growth markets including cardiovascular and robotic surgery while creating what CEO Joaquin Duato claims will be the largest orthopedics company in the medical device space. - Former Smith & Nephew CEO Namal Nawana will lead the new orthopedics company, which competes in lower-growth markets compared to J&J's other medtech segments. - Following the spinout, J&J's medtech division will concentrate on cardiovascular, surgery, and vision businesses, continuing the company's portfolio transformation strategy initiated with the 2021 Kenvue consumer health separation.
